InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.1667.

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of InflaRx in a research note on Tuesday, December 30th. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Friday. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. Finally, Guggenheim cut their price objective on InflaRx from $22.00 to $14.00 and set a “buy” rating for the company in a report on Friday, March 20th.

Institutional Trading of InflaRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its holdings in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares in the last quarter. Woodline Partners LP bought a new position in InflaRx in the 1st quarter valued at $766,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after buying an additional 91,927 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of InflaRx in the 2nd quarter valued at $262,000. Finally, Squarepoint Ops LLC raised its position in shares of InflaRx by 29.1% during the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after acquiring an additional 42,489 shares during the last quarter. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Stock Performance

InflaRx stock opened at $0.89 on Friday. InflaRx has a 52 week low of $0.71 and a 52 week high of $1.94. The firm has a market capitalization of $64.66 million, a PE ratio of -1.18 and a beta of 1.48. The business’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $1.11.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Friday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of ($0.04) million during the quarter, compared to analyst estimates of $0.03 million. Research analysts forecast that InflaRx will post -1.04 earnings per share for the current year.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.